Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 11, 2019. The document serves as a transaction notification regarding insider trading activities involving Persons Discharging Managerial Responsibilities (PDMR) and Persons Closely Associated (PCA) with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a regulatory disclosure of a specific share transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single transaction involving the transfer of 6,000 ordinary shares between a PDMR and their spouse.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed for nil consideration (£0.00) on February 8, 2019, and explicitly states there was no change in beneficial ownership.
Key Facts for Investor Verification
- Transaction Type: Transfer of 6,000 ordinary shares between Mr. Roger Connor (President, Global Vaccines) and his spouse, Mrs. Denise Connor.
- Consideration: Nil (£0.00).
- Beneficial Ownership: No change in beneficial ownership occurred.
- Transaction Date: February 8, 2019.
- Financial Data: This filing does not provide any financial results or operational metrics.